Humaid Al-Shamsi, The Chairman of Nexomic, CEO of Burjeel Cancer Institute (BCI) Comprehensive Cancer Center, shared on LinkedIn:
“Announcing a new partnership to de-risk oncology drug development and clinical trials.
Nexomic is partnering with Alpha Clinical to bring DECODE, Nexomic’s AI-powered multi-omic intelligence solution, into oncology clinical development programmes.
By combining Alpha Clinical Developments’ clinical trial strategy expertise with Nexomic’s ability to decode the biology of treatment response and resistance, we aim to help sponsors define biologically relevant patient populations and inform trial design, biomarker strategy, patient stratification and enrichment, enabling better development decisions earlier.”
Other articles featuring Humaid Al-Shamsi on OncoDaily.